Hépato-Gastro & Oncologie Digestive

Volume 31, supplement 5, September 2024

ÉDITORIAL

Towards the end of the intravenous route for infliximab? We’re getting close (p.5-6)
Xavier Roblin

MINI-REVUES

Switching from intravenous to subcutaneous infliximab: when and how? (p.7-12)
Anthony Buisson

Long-term data on the efficacy of subcutaneous infliximab switch: what does PEREM study tell us? (p.13-8)
Nicolas Mathieu

Patient satisfaction and experience after switching to a citrate-free high-concentration biosimilar adalimumab: data from the Yu-Matter study (p.19-23)
Guillaume Bouguen

Subcutaneous infliximab and anoperineal localisations: what are the results? (p.24-8)
Lucine Vuitton